RxDoctor Payments Data

Cody Matthews, DO

Family Medicine · High Point, NCNPI 1669769212

Payments from drug & device makers

$6,900in general payments, 2019–2025

Across 425 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Abbott$854
  • Pfizer$832
  • AbbVie$608
  • AstraZeneca$557
  • Lilly USA, LLC$440
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,880100%
  • Other$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,900 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$37,614
Medicare patients
106
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$110,097
EliquisApixaban84$65,387
MounjaroTirzepatide32$48,287
RybelsusSemaglutide27$39,404
FarxigaDapagliflozin Propanediol33$34,701
Tresiba Flextouch U-200Insulin Degludec15$20,516
Breo ElliptaFluticasone/Vilanterol28$16,855
Repatha SureclickEvolocumab16$14,573
JardianceEmpagliflozin14$11,927
LinzessLinaclotide19$10,938
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$8,426
XareltoRivaroxaban15$8,245
BelsomraSuvorexant12$5,095
SymbicortBudesonide/Formoterol Fumarate19$4,709
Atorvastatin Calcium338$3,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,055$149,50188 claims
PfizerEliquis$832$65,38784 claims
Lilly USA, LLCMounjaro$440$48,28732 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$557$47,83663 claims
GSKBreo Ellipta, Arnuity Ellipta$90$20,15240 claims
AbbVieLinzess, Synthroid$608$12,09631 claims
Boehringer IngelheimJardiance$169$11,92714 claims
Johnson & JohnsonXarelto$93$8,24515 claims
MerckBelsomra$26$5,09512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in High Point

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →